Research programme: antisense oligonucleotides - University Magna Graecia of Catanzaro/Exiqon

Drug Profile

Research programme: antisense oligonucleotides - University Magna Graecia of Catanzaro/Exiqon

Alternative Names: LNA-i-miR-221; miR17-92-i-PT

Latest Information Update: 06 May 2016

Price : $50

At a glance

  • Originator University "Magna Graecia" of Catanzaro
  • Class Antisense oligonucleotides
  • Mechanism of Action MicroRNA inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 06 May 2016 Pharmacodynamics from a preclinical study in Cancer presented at the 107th Annual Meeting of the American Association for Cancer Research (AACR-2016) (3183858; 3183867)
  • 16 Apr 2016 Preclinical trials in Cancer in Italy (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top